Zimmer Biomet Prices Secondary Offering
Zimmer Biomet saw its shares slide in Tuesday's session after the company announced the pricing of its previously disclosed underwritten secondary offering.
All Work
Chris Lange
NXP Semiconductors Initiates Plan for Key Asset Divestiture
NXP Semiconductors traded down slightly Tuesday morning after the announcement that it will divest its Standard Products business to a consortium of financial investors.
Pfizer and Shire Move on IBD License Agreement
Pfizer made waves early on Tuesday after it announced a new licensing deal with Shire for an investigational biologic.
SEC Settles Fraud Charges With California Muni Advisors
The U.S. Securities and Exchange Commission (SEC) recently announced that two California-based municipal advisory firms and their executives have agreed to settle charges that they used deceptive practices when soliciting the business of five…
PointClickCare Prepares for IPO
PointClickCare has amended its filing with the U.S. Securities and Exchange Commission (SEC) for its initial public offering (IPO).
Global Blood Therapeutics Sinks on Secondary Offering
Global Blood Therapeutics has filed with the SEC regarding a secondary offering valued up to $100 million.
MEDNAX Moves to Acquire Cardon
Mednax has announced that it will acquire Cardon Outreach, one of the nation's largest providers of integraded revenue cycle management services.
Symantec Rises on Blue Coat Acquisition
Symantec has announced that it has entered into a definitive agreement to acquire Blue Coat for roughly more than $4 billion in cash.
Why Marinus Pharmaceuticals Shares Are Sliding
Shares of Marinus Pharmaceuticals tumbled Monday morning after the company gave an update on top-line results from a Phase 3 clinical trial.
Why Eleven Biotherapeutics Is Making a Run
Eleven Biotherapeutics watched its shares climb early on Monday morning following a key FDA submission.
4 Companies That Punished Shareholders Last Week
Although the broad markets were at their highest levels on the year, some companies held them back from pushing even higher.
7 Biopharma Companies That Destroyed Shareholders Last Week
Biotech companies that lost their way last week truly burned shareholders, whether it was due to ASCO, earnings or even unfavorable clinical trial updates.
Top 4 Earnings to Look for in the Week Ahead
We only have a few major companies are expected to share their latest results this coming week. Coincidentally, all of these companies are reporting on Thursday.
SEC Issues Fraud Charges for Misleading Investors Through a Dating Site
The SEC has announced fraud charges and an asset freeze against a Connecticut man accused of misleading people into investing in his company, then taking their money for his personal use.
Sophiris Soars on Positive Phase 2 Results
Sophiris Bio shares absolutely skyrocketed on Friday following positive results from its Phase 2a proof of concept study of topsalysin in localized prostate cancer.
Merck Moves to Acquire Afferent Pharma
Merck and Afferent Pharmaceuticals reportedly have signed a definitive agreement under which the former will acquire the latter.
Global Blood Therapeutics Rises on Solid Mid-Stage Results
Shares of Global Blood Therapeutics saw a handy gain going into the weekend following positive results from its mid-stage clinical trial.
Was H&R Block Earnings Beat Enough for Investors?
H&R Block reported better-than-expected fiscal fourth-quarter financial results after the markets closed on Thursday.
SEC Settles Insider Trading Charges With Chinese Consultant
A former consultant to two China-based private equity firms has agreed to pay over $756,000 in order to settle SEC insider trading charges.
Cybersecurity Short Sellers Can’t Make Up Their Minds
The May 31 short interest data have been compared with the previous figures, and short interest moves for the selected cybersecurity stocks were mixed.